Literature DB >> 31376174

Reduction of skin innervation is associated with a severe fibromyalgia phenotype.

Dimitar Evdokimov1, Johanna Frank1, Alexander Klitsch1, Stefan Unterecker2, Bodo Warrings2, Jordi Serra3, Aikaterini Papagianni1, Nadine Saffer1, Caren Meyer Zu Altenschildesche1, Daniel Kampik4, Rayaz A Malik5, Claudia Sommer1, Nurcan Üçeyler1.   

Abstract

OBJECTIVE: To assess patterns and impact of small nerve fiber dysfunction and pathology in patients with fibromyalgia syndrome (FMS).
METHODS: One hundred seventeen women with FMS underwent neurological examination, questionnaire assessment, neurophysiology assessment, and small fiber tests: skin punch biopsy, corneal confocal microscopy, microneurography, quantitative sensory testing including C-tactile afferents, and pain-related evoked potentials. Data were compared with those of women with major depressive disorder and chronic widespread pain (MD-P) and healthy women.
RESULTS: Intraepidermal nerve fiber density (IENFD) was reduced at different biopsy sites in 63% of FMS patients (MD-P: 10%, controls: 18%; p < 0.001 for each). We found 4 patterns of skin innervation in FMS: normal, distally reduced, proximally reduced, and both distally and proximally reduced (p < 0.01 for each compared to controls). Microneurography revealed initial activity-dependent acceleration of conduction velocity upon low frequencies of stimulation in 1A fibers, besides 1B fiber spontaneous activity and mechanical sensitization in FMS patients. FMS patients had elevated warm detection thresholds (p < 0.01), impaired C-tactile afferents (p < 0.05), and reduced amplitudes (p < 0.001) of pain-related evoked potentials compared to controls. Compared to FMS patients with normal skin innervation, those with generalized IENFD reduction had higher pain intensity and impairment due to pain, higher disease burden, more stabbing pain and paresthesias, and more anxiety (p < 0.05 for each). FMS patients with generalized IENFD reduction also had lower corneal nerve fiber density (p < 0.01) and length (p < 0.05).
INTERPRETATION: The extent of small fiber pathology is related to symptom severity in FMS. This knowledge may have implications for the diagnostic classification and treatment of patients with FMS. ANN NEUROL 2019;86:504-516.
© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.

Entities:  

Year:  2019        PMID: 31376174     DOI: 10.1002/ana.25565

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

Review 1.  The puzzle of fibromyalgia between central sensitization syndrome and small fiber neuropathy: a narrative review on neurophysiological and morphological evidence.

Authors:  Marina de Tommaso; Eleonora Vecchio; Maria Nolano
Journal:  Neurol Sci       Date:  2022-01-14       Impact factor: 3.307

2.  Unbiased immune profiling reveals a natural killer cell-peripheral nerve axis in fibromyalgia.

Authors:  Vivek Verma; Gillian L Drury; Marc Parisien; Ayşe N Özdağ Acarli; Tho-Alfakar Al-Aubodah; Anastasia Nijnik; Xia Wen; Nicol Tugarinov; Maria Verner; Richie Klares; Alexander Linton; Emerson Krock; Carlos E Morado Urbina; Bendik Winsvold; Lars G Fritsche; Egil A Fors; Ciriaco Piccirillo; Arkady Khoutorsky; Camilla I Svensson; Mary A Fitzcharles; Pablo M Ingelmo; Nicole F Bernard; Franck P Dupuy; Nurcan Üçeyler; Claudia Sommer; Irah L King; Carolina B Meloto; Luda Diatchenko
Journal:  Pain       Date:  2021-09-24       Impact factor: 7.926

3.  Deletion of the Gene Encoding the NMDA Receptor GluN1 Subunit in Schwann Cells Causes Ultrastructural Changes in Remak Bundles and Hypersensitivity in Pain Processing.

Authors:  Coralie Brifault; Haylie Romero; Alicia Van-Enoo; Don Pizzo; Pardis Azmoon; HyoJun Kwon; Chanond Nasamran; Steven L Gonias; Wendy M Campana
Journal:  J Neurosci       Date:  2020-10-13       Impact factor: 6.167

4.  Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Phillip Joseph; Carlo Arevalo; Rudolf K F Oliveira; Mariana Faria-Urbina; Donna Felsenstein; Anne Louise Oaklander; David M Systrom
Journal:  Chest       Date:  2021-02-10       Impact factor: 10.262

5.  Characterization of dermal skin innervation in fibromyalgia syndrome.

Authors:  Dimitar Evdokimov; Philine Dinkel; Johanna Frank; Claudia Sommer; Nurcan Üçeyler
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

6.  MiR103a-3p and miR107 are related to adaptive coping in a cluster of fibromyalgia patients.

Authors:  Alexandra Braun; Dimitar Evdokimov; Johanna Frank; Claudia Sommer; Nurcan Üçeyler
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

7.  Epidermal Neurite Density in Skin Biopsies From Patients With Juvenile Fibromyalgia.

Authors:  Alexis Boneparth; Shan Chen; Daniel B Horton; L Nandini Moorthy; Ian Farquhar; Heather M Downs; Hang Lee; Anne Louise Oaklander
Journal:  J Rheumatol       Date:  2020-08-15       Impact factor: 4.666

8.  Diagnosing small fiber neuropathy in clinical practice: a deep phenotyping study.

Authors:  Nadine Egenolf; Caren Meyer Zu Altenschildesche; Luisa Kreß; Katja Eggermann; Barbara Namer; Franziska Gross; Alexander Klitsch; Tobias Malzacher; Daniel Kampik; Rayaz A Malik; Ingo Kurth; Claudia Sommer; Nurcan Üçeyler
Journal:  Ther Adv Neurol Disord       Date:  2021-03-23       Impact factor: 6.570

Review 9.  Studying human nociceptors: from fundamentals to clinic.

Authors:  Steven J Middleton; Allison M Barry; Maddalena Comini; Yan Li; Pradipta R Ray; Stephanie Shiers; Andreas C Themistocleous; Megan L Uhelski; Xun Yang; Patrick M Dougherty; Theodore J Price; David L Bennett
Journal:  Brain       Date:  2021-06-22       Impact factor: 15.255

10.  Reduced activity, reactivity and functionality of the sympathetic nervous system in fibromyalgia: An electrodermal study.

Authors:  Gustavo A Reyes Del Paso; Pablo de la Coba
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.